DaVita (NYSE:DVA) Issues FY 2024 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 9.250-10.050 for the period, compared to the consensus earnings per share estimate of 9.790. The company issued revenue guidance of -. DaVita also updated its FY24 guidance to $9.25-$10.05 EPS.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DVA. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Bank of America lifted their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial raised their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, TD Cowen upped their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $159.00.

DaVita Stock Performance

Shares of DVA traded up $1.27 during mid-day trading on Tuesday, reaching $158.32. The company’s stock had a trading volume of 1,266,738 shares, compared to its average volume of 805,333. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. DaVita has a 1-year low of $75.47 and a 1-year high of $168.50. The business has a 50-day simple moving average of $158.40 and a two-hundred day simple moving average of $146.05. The stock has a market cap of $13.28 billion, a P/E ratio of 16.86, a PEG ratio of 0.90 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.08 earnings per share. As a group, equities research analysts anticipate that DaVita will post 9.99 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 in the last three months. 2.00% of the stock is currently owned by company insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.